Cargando…
Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments †
Since the discovery of camelid heavy-chain antibodies in 1993, there has been tremendous excitement for these antibody domains (VHHs/sdAbs/nanobodies) as research tools, diagnostics, and therapeutics. Commercially, several patents were granted to pioneering research groups in Belgium and the Netherl...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100996/ https://www.ncbi.nlm.nih.gov/pubmed/35563400 http://dx.doi.org/10.3390/ijms23095009 |